交易 BioCryst - BCRX CFD
新增到我的最愛- 摘要
- 曆史數據
- 活動
- 盈虧控制
- 資産負債表
- 現金流
交易條件
價差 | 0.05 | ||||||||
多頭倉位隔夜費用
多頭隔夜費用
前往平台 | -0.026179% | ||||||||
空頭倉位隔夜費用
空頭隔夜費用
前往平台 | 0.003957% | ||||||||
隔夜費時間 | 21:00 (UTC) | ||||||||
最小成交量 | 1 | ||||||||
貨幣 | USD | ||||||||
保證金 | 5% | ||||||||
股票交易 | United States of America | ||||||||
交易委員會 | 0% |
*Information provided by Capital.com
BioCryst Pharmaceuticals Inc ESG Risk Ratings
High Medium Low Negligible
“C”分數表示在公開報告重大 ESG 數據方面令人滿意的相對 ESG 表現和適度的透明度。
- 上週
- 上個月
- 去年
- 過去兩年
- 最大
- 每日
- 每週
- 每月
日期 | 拋售 | 自訂 | 變化 (%) | 打開 | 最高 | 最小 |
---|---|---|---|---|---|---|
Apr 16, 2024 | 4.59 | 0.00 | 0.00% | 4.59 | 4.69 | 4.52 |
Apr 15, 2024 | 4.65 | -0.07 | -1.48% | 4.72 | 4.76 | 4.57 |
Apr 12, 2024 | 4.75 | -0.33 | -6.50% | 5.08 | 5.13 | 4.68 |
Apr 11, 2024 | 5.08 | 0.16 | 3.25% | 4.92 | 5.09 | 4.80 |
Apr 10, 2024 | 4.85 | 0.21 | 4.53% | 4.64 | 4.88 | 4.54 |
Apr 9, 2024 | 4.78 | 0.18 | 3.91% | 4.60 | 4.85 | 4.59 |
Apr 8, 2024 | 4.58 | -0.03 | -0.65% | 4.61 | 4.64 | 4.52 |
Apr 5, 2024 | 4.58 | 0.07 | 1.55% | 4.51 | 4.63 | 4.44 |
Apr 4, 2024 | 4.57 | -0.19 | -3.99% | 4.76 | 4.81 | 4.56 |
Apr 3, 2024 | 4.71 | 0.08 | 1.73% | 4.63 | 4.74 | 4.57 |
Apr 2, 2024 | 4.66 | -0.26 | -5.28% | 4.92 | 4.98 | 4.66 |
Apr 1, 2024 | 5.03 | 0.01 | 0.20% | 5.02 | 5.06 | 4.88 |
Mar 28, 2024 | 5.05 | -0.13 | -2.51% | 5.18 | 5.31 | 5.05 |
Mar 27, 2024 | 5.12 | 0.06 | 1.19% | 5.06 | 5.18 | 4.95 |
Mar 26, 2024 | 4.98 | -0.02 | -0.40% | 5.00 | 5.12 | 4.97 |
Mar 25, 2024 | 4.89 | -0.07 | -1.41% | 4.96 | 5.05 | 4.81 |
Mar 22, 2024 | 4.99 | -0.46 | -8.44% | 5.45 | 5.45 | 4.99 |
Mar 21, 2024 | 5.46 | -0.02 | -0.36% | 5.48 | 5.85 | 5.43 |
Mar 20, 2024 | 5.45 | 0.14 | 2.64% | 5.31 | 5.46 | 5.15 |
Mar 19, 2024 | 5.33 | 0.30 | 5.96% | 5.03 | 5.40 | 5.01 |
BioCryst Events
時間 (UTC) | 國家 | 事件 |
---|---|---|
Wednesday, May 1, 2024 | ||
時間 (UTC) 12:30 | 國家 US
| 事件 Q1 2024 BioCryst Pharmaceuticals Inc Earnings Release Q1 2024 BioCryst Pharmaceuticals Inc Earnings ReleaseForecast(預報) -返回 - |
Wednesday, June 12, 2024 | ||
時間 (UTC) 14:00 | 國家 US
| 事件 BioCryst Pharmaceuticals Inc Annual Shareholders Meeting BioCryst Pharmaceuticals Inc Annual Shareholders MeetingForecast(預報) -返回 - |
Thursday, August 1, 2024 | ||
時間 (UTC) 12:30 | 國家 US
| 事件 Q2 2024 BioCryst Pharmaceuticals Inc Earnings Release Q2 2024 BioCryst Pharmaceuticals Inc Earnings ReleaseForecast(預報) -返回 - |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
總收入 | 270.827 | 157.17 | 17.812 | 48.835 | 20.653 |
收入 | 270.827 | 157.17 | 17.812 | 48.835 | 20.653 |
收入成本,共計 | 6.594 | 7.264 | 1.676 | 4.101 | 0.471 |
毛利 | 264.233 | 149.906 | 16.136 | 44.734 | 20.182 |
總營業費用 | 419.262 | 279.052 | 194.58 | 148.29 | 114.873 |
銷售/一般/行政費用,總計 | 159.371 | 118.818 | 67.929 | 37.121 | 13.614 |
研究與開發 | 253.297 | 208.808 | 122.964 | 107.068 | 84.888 |
營業收入 | -148.435 | -121.882 | -176.768 | -99.455 | -94.22 |
利息收入(費用),非經營淨值 | -95.948 | -59.927 | -6.046 | -9.442 | -7.032 |
稅前淨收入 | -244.383 | -181.809 | -182.814 | -108.897 | -101.252 |
稅後淨收入 | -247.116 | -184.062 | -182.814 | -108.897 | -101.252 |
未計算非常項目前的淨收益 | -247.116 | -184.062 | -182.814 | -108.897 | -101.252 |
淨收入 | -247.116 | -184.062 | -182.814 | -108.897 | -101.252 |
普通股股東可獲收益 (不含非經常性項目) | -247.116 | -184.062 | -182.814 | -108.897 | -101.252 |
普通股股東可獲收益 (含非經常性項目) | -247.116 | -184.062 | -182.814 | -108.897 | -101.252 |
攤薄淨收入 | -247.116 | -184.062 | -182.814 | -108.897 | -101.252 |
攤薄後加權平均股 | 185.908 | 179.117 | 167.267 | 115.6 | 103.185 |
扣除特別項目的每股攤薄盈利 | -1.32924 | -1.02761 | -1.09295 | -0.94202 | -0.98127 |
Dividends per Share - Common Stock Primary Issue | |||||
每股正常攤薄盈利 | -1.32924 | -1.23024 | -1.08092 | -0.94202 | -0.82717 |
非常規項目總計 | |||||
異常費用(收入) | 0 | -55.838 | 2.011 | 15.9 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
總收入 | 82.491 | 68.778 | 79.545 | 75.827 | 65.532 |
收入 | 82.491 | 68.778 | 79.545 | 75.827 | 65.532 |
收入成本,共計 | 0.95 | 0.938 | 2.496 | 3.613 | 0.247 |
毛利 | 81.541 | 67.84 | 77.049 | 72.214 | 65.285 |
總營業費用 | 132.213 | 97.193 | 125.856 | 93.272 | 100.254 |
銷售/一般/行政費用,總計 | 50.997 | 47.867 | 50.153 | 36.919 | 38.017 |
研究與開發 | 51.247 | 48.388 | 73.207 | 52.74 | 61.99 |
營業收入 | -49.722 | -28.415 | -46.311 | -17.445 | -34.722 |
利息收入(費用),非經營淨值 | -24.864 | -24.247 | -25.154 | -23.553 | -23.281 |
稅前淨收入 | -74.586 | -52.662 | -71.465 | -40.998 | -58.003 |
稅後淨收入 | -75.326 | -53.333 | -71.541 | -42.52 | -58.859 |
未計算非常項目前的淨收益 | -75.326 | -53.333 | -71.541 | -42.52 | -58.859 |
淨收入 | -75.326 | -53.333 | -71.541 | -42.52 | -58.859 |
普通股股東可獲收益 (不含非經常性項目) | -75.326 | -53.333 | -71.541 | -42.52 | -58.859 |
普通股股東可獲收益 (含非經常性項目) | -75.326 | -53.333 | -71.541 | -42.52 | -58.859 |
攤薄淨收入 | -75.326 | -53.333 | -71.541 | -42.52 | -58.859 |
攤薄後加權平均股 | 189.118 | 188.509 | 186.934 | 186.18 | 185.605 |
扣除特別項目的每股攤薄盈利 | -0.3983 | -0.28292 | -0.38271 | -0.22838 | -0.31712 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常攤薄盈利 | -0.29856 | -0.28292 | -0.38271 | -0.22838 | -0.31712 |
異常費用(收入) | 29.019 | 0 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流動資産總額 | 516.5 | 566.136 | 323.8 | 164.345 | 114.352 |
現金和短期投資 | 424.31 | 507.601 | 300.366 | 136.226 | 104.467 |
現金等價物 | 304.767 | 504.389 | 272.127 | 114.172 | 26.731 |
短期投資 | 119.543 | 3.212 | 28.239 | 22.054 | 77.736 |
應收賬款總額,淨額 | 50.599 | 29.413 | 8.646 | 22.146 | 4.293 |
應收賬款 - 貿易,淨額 | 50.599 | 29.413 | 8.646 | 22.146 | 4.293 |
總庫存 | 27.533 | 15.791 | 7.039 | 0 | 1.649 |
預付的費用 | 12.586 | 9.986 | 5.528 | 4.422 | 2.39 |
其他流動資産,總計 | 1.472 | 3.345 | 2.221 | 1.551 | 1.553 |
總資産 | 550 | 588.151 | 334.715 | 175.282 | 146.841 |
物業/廠房/設備,總計 - 淨額 | 15.423 | 15.186 | 10.915 | 10.937 | 9.135 |
物業/廠房/設備,總計 - 總額 | 29.322 | 25.925 | 20.892 | 18.911 | 15.23 |
累計折舊,總計 | -13.899 | -10.739 | -9.977 | -7.974 | -6.095 |
長期投資 | 18.077 | 6.829 | 0 | 22.376 | |
其他長期資産,總計 | 0.978 | ||||
流動負債總額 | 105.514 | 103.718 | 105.654 | 92.335 | 69.477 |
應付賬款 | 14.356 | 27.808 | 18.713 | 13.988 | 7.769 |
預提費用 | 89.934 | 74.489 | 56.791 | 37.646 | 27.739 |
應付票據/短期債務 | 0 | 0 | 30 | 29.561 | 29.121 |
其他流動負債,總計 | 1.224 | 1.421 | 0.15 | 2.12 | 0.221 |
負債總額 | 844.597 | 695.137 | 353.977 | 137.03 | 97.606 |
長期債務總額 | 733.279 | 585.457 | 244.452 | 41.289 | 28.075 |
長期債務 | 733.279 | 585.457 | 244.452 | 41.289 | 25.372 |
資本租賃義務 | 2.703 | ||||
其他負債,總計 | 5.804 | 5.962 | 3.871 | 3.406 | 0.054 |
股權 | -294.597 | -106.986 | -19.262 | 38.252 | 49.235 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
普通股 | 1.879 | 1.843 | 1.769 | 1.541 | 1.101 |
額外實收資本 | 1158.12 | 1098.5 | 1002.41 | 877.3 | 780.4 |
留存收益(累計赤字) | -1454.62 | -1207.5 | -1023.44 | -840.628 | -731.969 |
其他權益,總計 | 0.026 | 0.177 | 0.003 | 0.039 | -0.297 |
總負債和股東權益 | 550 | 588.151 | 334.715 | 175.282 | 146.841 |
已發行普通股總數 | 187.906 | 184.35 | 176.883 | 154.082 | 110.063 |
長期債務的當前部分/資本租賃 | 0 | 9.02 | 4.627 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
流動資産總額 | 502.466 | 511.056 | 490.883 | 516.5 | 509.001 |
現金和短期投資 | 397.59 | 410.67 | 398.158 | 424.31 | 426.858 |
現金等價物 | 150.905 | 146.215 | 155.136 | 304.767 | 246.899 |
短期投資 | 246.685 | 264.455 | 243.022 | 119.543 | 179.959 |
應收賬款總額,淨額 | 53.646 | 57.667 | 48.639 | 50.599 | 42.61 |
應收賬款 - 貿易,淨額 | 53.646 | 57.667 | 48.639 | 50.599 | 42.61 |
總庫存 | 29.63 | 27.033 | 27.466 | 27.533 | 27.019 |
預付的費用 | 20.016 | 14.112 | 15.157 | 12.586 | 11.07 |
其他流動資産,總計 | 1.584 | 1.574 | 1.463 | 1.472 | 1.444 |
總資産 | 522.924 | 529.885 | 509.737 | 550 | 558.594 |
物業/廠房/設備,總計 - 淨額 | 20.379 | 15.384 | 15.422 | 15.423 | 15.261 |
物業/廠房/設備,總計 - 總額 | 17.73 | 12.397 | 11.924 | 11.155 | 10.671 |
累計折舊,總計 | -6.35 | -5.451 | -4.878 | -4.349 | -3.874 |
流動負債總額 | 90.763 | 93.498 | 85.157 | 105.514 | 81.637 |
應付賬款 | 10.567 | 13.889 | 6.254 | 14.356 | 8.622 |
預提費用 | 79.674 | 77.83 | 77.703 | 89.934 | 71.461 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 0.522 | 1.779 | 1.2 | 1.224 | 1.554 |
負債總額 | 933.91 | 918.598 | 838.024 | 844.597 | 801.253 |
長期債務總額 | 833.181 | 819.297 | 746.933 | 733.279 | 713.648 |
長期債務 | 833.181 | 819.297 | 746.933 | 733.279 | 713.648 |
其他負債,總計 | 9.966 | 5.803 | 5.934 | 5.804 | 5.968 |
股權 | -410.986 | -388.713 | -328.287 | -294.597 | -242.659 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
普通股 | 1.898 | 1.895 | 1.889 | 1.879 | 1.864 |
額外實收資本 | 1205.74 | 1191.98 | 1177.19 | 1158.12 | 1138.65 |
留存收益(累計赤字) | -1619.43 | -1583.28 | -1507.95 | -1454.62 | -1383.08 |
其他權益,總計 | 0.8 | 0.69 | 0.585 | 0.026 | -0.098 |
總負債和股東權益 | 522.924 | 529.885 | 509.737 | 550 | 558.594 |
已發行普通股總數 | 189.803 | 189.491 | 188.883 | 187.906 | 186.411 |
長期投資 | 0 | 3.445 | 3.432 | 18.077 | 34.332 |
其他長期資産,總計 | 0.079 |
- 每年
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
淨收入/起跑線 | -247.116 | -184.062 | -182.814 | -108.897 | -101.252 |
經營活動産生的現金 | -161.85 | -142.157 | -135.108 | -89.584 | -92.565 |
經營活動産生的現金 | 1.437 | 0.777 | 0.748 | 0.724 | 0.77 |
非現金物品 | 142.774 | 33.004 | 20.083 | 19.461 | 11.447 |
營運資金的變化 | -58.945 | 8.124 | 26.875 | -0.872 | -3.53 |
投資活動産生的現金 | -128.238 | 15.804 | -6.856 | 77.934 | 4.768 |
資本支出 | -1.351 | -2.385 | -0.514 | -0.343 | -0.366 |
其他投資現金流量項目,總計 | -126.887 | 18.189 | -6.342 | 78.277 | 5.134 |
融資活動産生的現金 | 88.027 | 359.668 | 300.589 | 99.098 | 62.504 |
股票的發行(報廢),淨額 | 14.955 | 65.794 | 110.542 | 79.621 | 56.252 |
債務的發行(退還),淨額 | 73.072 | 293.874 | 190.047 | 19.477 | 6.252 |
現金淨變化 | -201.495 | 233.386 | 158.625 | 87.448 | -25.293 |
外彙效應 | 0.566 | 0.071 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -53.333 | -247.116 | -175.575 | -133.055 | -74.196 |
Cash From Operating Activities | -47.512 | -161.85 | -138.001 | -105.557 | -77.8 |
Cash From Operating Activities | 0.405 | 1.437 | 1.041 | 0.652 | 0.317 |
Non-Cash Items | 33.074 | 142.774 | 83.72 | 56.105 | 28.634 |
Changes in Working Capital | -27.658 | -58.945 | -47.187 | -29.259 | -32.555 |
Cash From Investing Activities | -107.109 | -128.238 | -205.453 | -135.91 | -38.472 |
Capital Expenditures | -0.16 | -1.351 | -0.825 | -0.65 | -0.406 |
Other Investing Cash Flow Items, Total | -106.949 | -126.887 | -204.628 | -135.26 | -38.066 |
Cash From Financing Activities | 5.077 | 88.027 | 83.828 | 7.503 | 7.356 |
Issuance (Retirement) of Stock, Net | 5.077 | 14.955 | 10.756 | 7.503 | 7.356 |
Net Change in Cash | -149.64 | -201.495 | -259.391 | -233.715 | -108.876 |
Foreign Exchange Effects | -0.096 | 0.566 | 0.235 | 0.249 | 0.04 |
Issuance (Retirement) of Debt, Net | 73.072 | 73.072 |
差價合約交易計算器
計算您的假設損益
交易佣金
0
- 1:1
槓桿
1:1
- 20
- 100
- 500
- 1000
- 10000
交易
交易規模(槓桿 x 投資):
打開
拋售
已賣出 做多
Industry: | Bio Therapeutic Drugs |
4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US
盈虧控制
- Annual
- Quarterly
人們也觀看
還在尋找值得信賴的經紀商?
加入全球 610,000 多名交易者,選擇與 Capital.com 交易